The pharmaceutical giant will pay USD221.50 per share in cash to purchase the US biotech company, which has developed an innovative platform called drug-Fc conjugates (DFCs).
Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.